Last reviewed 18 August 2026 · Trust Center / change history
Cooling belongs at the point of care.
AIRCHILL is a development-stage emergency-ventilation platform exploring controlled respiratory cooling as an integrated intervention for time-critical care. We are building the engineering, evidence, regulatory and reimbursement pathway in parallel.
Minutes after the event; the axis is non-linear so the first hour stays readable. Heatstroke and eligible neonatal HIE have explicit early treatment windows, but post-cardiac-arrest temperature control is a different evidence question. The TTM2 marker is deliberately labelled DERIVED: the main RCT reported a median of 3 hours from intervention start to 34 °C, while a TTM2 substudy reported roughly 2 hours from arrest to randomisation in its analysed cohort; combining them gives only an approximate ≈5-hour visual context, not a directly reported TTM2 event-to-target endpoint. Current ERC–ESICM guidance emphasizes temperature control and fever prevention after ROSC rather than treating earlier/deeper hypothermia as a proven universal benefit. Together with AIRCHILL’s porcine mechanism data and the broader animal timing/dose literature, this supports a testable timing hypothesis—not an efficacy claim. POLAR likewise shows that timing alone is not enough, so AIRCHILL studies must prospectively test route, thermal distribution and phenotype together with timing.
Concept renderingPlatform concept, rendering 2019 — ventilation, controlled cooling and a detachable control unit. What exists today is a TRL ≈ 4 demonstrator.
One stack. Ventilation and controlled cooling.
A design concept from 2019 — a rendering, not a photograph of a finished device. What exists today is the laboratory demonstrator that carried the preclinical work.
- In the first product
- Transport ventilation with controlled respiratory cooling in one gas path.
- Additional hardware modules
- Most additional hardware is not planned as proprietary subsystem R&D. Monitoring, suction, ECG/defibrillation and telemedicine are intended primarily as established purchased components, OEM modules or standard interfaces. Where their regulatory impact is proportionate, AIRCHILL can integrate them into the first certifiable platform instead of first certifying an artificially stripped-down device and then rebuilding it. The work remains real but shifts from inventing the subsystem to component selection, supplier qualification, interface engineering, electrical/software compatibility, risk management and verification of the complete integrated medical device.
- Build state
- TRL ≈ 4 · no design freeze · no CE marking